SBNO1: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: SBNO1

NCBI ID: G55206

SBNO1

Other Name(s): FLJ10701 | monocyte protein 3 | Monocyte protein 3 | MOP-3 | Protein strawberry notch homolog 1 (isoform 1) | FLJ14066 | SBNO1 variant 1 | FLJ35199 | Sno | SBNO1_HUMAN | strawberry notch homolog 1 | MOP3 | FLJ10833 | FLJ16176 | Strawberry notch homolog 1, transcript variant 1 | Protein strawberry notch homolog 1

SBNO1: A Potential Drug Target for Cancer and Neurodegenerative Diseases

SBNO1 (FLJ10701) is a protein that is expressed in various tissues of the body, including the brain, heart, and lungs. It is a member of the Smin family of proteins, which are involved in various cellular processes, including cell signaling and division. SBNO1 has been identified as a potential drug target (or biomarker) due to its involvement in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SBNO1 functions as a negative regulator of the nuclear factor of activated T cells (NFAT), a transcription factor that plays a role in the development and maintenance of T cells, which are a type of immune cell that play a critical role in protecting the body against infection and disease. SBNO1 helps to prevent NFAT from activating, which can lead to the production of immune cells that are involved in inflammation and tissue damage.

SBNO1 has been shown to be involved in the development of various diseases, including cancer. For example, studies have shown that high levels of SBNO1 are associated with an increased risk of cancer. Additionally, SBNO1 has been shown to promote the growth and survival of cancer cells, which can be a potential mechanism for its involvement in cancer development.

SBNO1 has also been shown to be involved in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells, which can lead to a range of symptoms, including cognitive decline and behavioral changes. SBNO1 has been shown to promote the production of toxic oxygen species (O2鈥?-), which can contribute to the damage caused by these conditions.

In addition to its involvement in cancer and neurodegenerative diseases, SBNO1 has also been shown to be involved in autoimmune disorders. These conditions involve the immune system attacking the body's own tissues, which can lead to a range of symptoms, including inflammation and autoimmune disease. SBNO1 has been shown to promote the production of immune cells that are involved in autoimmune disorders, which can contribute to the development and progression of these conditions.

Despite its potential as a drug target, SBNO1 has not yet been studied extensively, and more research is needed to fully understand its role in various diseases. Additionally, the development of potential drugs that target SBNO1 will require the development of new techniques for its identification and isolation, as well as the testing of potential therapeutic approaches.

In conclusion, SBNO1 is a protein that has been identified as a potential drug target (or biomarker) due to its involvement in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand its role in these conditions and the development of potential drugs that target SBNO1.

Protein Name: Strawberry Notch Homolog 1

The "SBNO1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SBNO1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets